Pathological and molecular progression of astrocytomas in a GFAP: 12V-Ha-Ras mouse astrocytoma model

American Journal of Pathology

Volumn 167, Issue 3, 2005, Pages 859-867

  Shannon, Patrick ^a   Sabha, Nesrin ^b   Lau, Nelson ^b   Kamnasaran, Deepak ^b   Gutmann, David H ^c   Guha, Abhijit ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P53; RAS PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOMA; CANCER INCIDENCE; CELL HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC ENGINEERING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE H RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENIC MOUSE;

EID: 24044492207     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62057-3     Document Type: Article

References (30)

1. Kleihues P, Cavanee WK (Eds): Pathology and Genetics of Brain Tumors. Lyon, IARC Press, 2000
2. Weiss W, Israel M, Cobbs C, Holland E, James D, Louis D, Marks C, McClatchey A, Roberts T, Van Dyke T, Wetmore C, Chiu I-M, Giovannini M, Guha A, Higgins R, Marino S, Radovanovic I, Reilly K, Aldape K: Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 2002, 21:7453-7463
3. Ding H, Nagy A, Gutmann D, Guha A: Astrocytoma models. Neurosurg Focus 2000, 8:1-7
4. Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, Gutmann DH, Squire JA, Nagy A, Guha A: Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001, 61:3826-3836
5. Guha A, Feldkamp M, Lau N, Boss G, Pawson A: Proliferation of human malignant astrocytomas are dependent on Ras activation. Oncogene 1997, 15:2755-2766
6. Feldkamp M, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 1999, 18:7514-7526
7. Feldkamp M, Lau N, Roncari L, Guha A: Isotype-specific Ras-GTP-levels predict the efficacy of farnesyl-transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 2001, 61:4425-4431
8. Reifen berger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer P, Collins VP: Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res 1996, 56:5141-5145
9. Ding H, Roncari L, Wu X, Shannon P, Nagy A, Guha A: Expression and hypoxio regulation of angiopoietins in human astrocytomas. Neurooncology 2001, 3:1-10
10. Ding H, Guha A: Mouse astrocytoma models: embryonic stem cell mediated transgenesis. J Neurooncol 2001, 53:289-296
11. McCarthy KD, de Vellis J: Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 1980, 85:890-902
12. Salim EI: Carcinogenicity of dimethylarsinic acid in p53 heterozygous knockout and wild-type C57BL/6J mice. J Carcinog 2003, 24:335-342
13. Feldkamp M, Lau N, Rak J, Kerbel R. Guha A: Astrocytoma cell lines express high levels of vascular endothelial growth factor (VEGF), which is reduced by inhibition of the Ras signaling pathway. Int J Cancer 1999, 81:118-124
14. Provias JP, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A: Meningiomas: the role of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) in angiogenesis and peri-tumoral edema. Neurosurgery 1997, 40:1016-1026
15. Salhia B, Angelov L, Roncari L, Wu X, Shannon P, Guha A: Induction of neoangiogenesis by reactive astrocytes. Brain Res 2000, 883:87-97
16. Dahlstrand J, Collins VP, Lendahl U: Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992, 52:5334-5341
17. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002, 39:193-206
18. Jaworski DM, Kelly GM, Hockfield S: Intracranial injury acutely induces the expression of the secreted isoform of the CNS-specific hyaluronan-binding protein BEHAB/brevican. Exp Neurol 1999, 157:327-378
19. Lantos PL, Pilkington GJ: The development of experimental brain tumors. A sequential light and electron microscope study of the subependymal plate. Early lesions (abnormal cell clusters). Acta Neuropathol 1979, 45:167-175
20. Schiffer D, Giordana MT, Pezotta S, Lechner C, Paoletti P: Cerebral tumors induced by transplacental ENU. Study of different tumoral stages, particularly of early proliferations. Acta Neuropathol 1978, 41:27-31
21. Naito M, Aoyama H, Naito Y, Fujioka Y, Ito A: Morphological and immunohistochemical evidence for the presence of subcortical target cells of N-ethyl-N-nitrosourea-induced cerebellar tumors in rats. Cancer Res 1986, 46:5836-5841
22. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P: p53 mutations in non astrocytic human brain tumors. Cancer Res 1991, 51:6202-6205
23. Cunningham J, Lust JA, Schaid DJ, Bren GD, Carpenter HA, Rizza E, Kovach JS, Thibodeau SN: Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992, 52:1974-1980
24. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN: Base transitions are the most frequent genetic changes at P53 in gastric cancer. Cancer Res 1993, 53:2614-2617
25. Zou M, Shi Y, Farid NR: p53 mutations in all stages of thyroid carcinoma. J Clin Endocrinol Metab 1993, 77:1054-1058
26. Craigo J, Hopkins M, DeLucia A: Uterine cervix adenocarcinoma with both human papillomavirus type 18 and tumor suppressor gene p53 mutation from a woman having an intact hymen. Gynecol Oncol 1995, 59:423-426
27. Slebos RJ, Baas IO, Clement M, Polak M, Mulder JW, van den Berg FM, Hamilton SR, Offerhaus GJ: Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 1996, 74:165-171
28. Ding H, Shannon P, Lau N, Roncari L, Wu X, Gutmann D, Nagy A, Guha A: Astrocyte-specific expression of activated p21 ras and constitutively active form of EGFR results in malignant oligodendroglioma formation. Cancer Res 2003, 63:1106-1113
29. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ: The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci USA 1994, 91:5124-5128
30. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ, Fagin JA: The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000, 19:3948-3954